Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1060571 | 0.83 | TRPA1 (0.69) | TRPA1ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL1065288 | 0.82 | TRPA1 (0.71) | TRPA1ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL17626221 | 0.79 | PORCN (0.61) | TRPA1TP53RXFP1 | |
| SCHEMBL2695577 | 0.76 | TRPA1 (0.67) | TRPA1ALDH1A1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL7318570 | 0.75 | GDA (0.55) | TRPA1RAB9ASMN1; SMN2HPGDNPC1 | |
| SCHEMBL2695674 | 0.75 | TRPA1 (0.64) | TRPA1ALDH1A1RAB9AHPGDMEN1 | |
| SCHEMBL1064155 | 0.75 | TRPA1 (1.00) | TRPA1MEN1KMT2ATP53RXFP1 | |
| SCHEMBL1065848 | 0.74 | GDA (0.53) | ALDH1A1 | |
| SCHEMBL2695622 | 0.73 | TRPA1 (0.71) | TRPA1ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL2693750 | 0.73 | TRPA1 (0.62) | TRPA1ALDH1A1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351567-B2 | Methods and compositions for treating pain | ELI LILLY AND COMPANY (US) | 2019-07-16 | — | — | US | disclosed |
| US-10351567-B2 | Methods and compositions for treating pain | ELI LILLY AND COMPANY (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2019-06-27 | — | — | US | disclosed |
| US-9951073-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | HYDRA BIOSCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20180093986-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180093986-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180093986-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2018-04-05 | — | — | US | disclosed |
| US-9815838-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815838-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815838-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ELI LILLY AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1962855-A2 | TRPA1 INHIBITORS FOR TREATING PAIN | Hydra Biosciences, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007073505-A2 | TRPA1 INHIBITORS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007073505-A2 | TRPA1 INHIBITORS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351567-B2 | Methods and compositions for treating pain | ACHE, COL2A1, MMP8 | TRPA1 59/4885ALDH1A1 540/4885RAB9A 3906/4885 |
| US-20180093986-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | TRPA1 59/4885ALDH1A1 540/4885RAB9A 3906/4885 |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | TRPA1 123/4885ALDH1A1 1104/4885RAB9A 1580/4885 |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | TRPA1 59/4885ALDH1A1 540/4885RAB9A 3906/4885 |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885ALDH1A1 313/4885RAB9A 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.